I try to pick up credible info from this board. I rarely post. I wanted to paste the following chart for the rookies, myself included. Could it be possible that companies that have a vested interest in seeing their drug continue to prosper might poke holes in anything that may challenge those sales? As you can see from this chart Novolog has a nice little racket going here. If Mannkind and Afrezza penetrate this market what would happen to the sales of Novolog? There are some very smart people involved with making sure Afrezza does not go to market. There are billions of dollars at stake. So who is actually writing these hit pieces? What are they being paid to write them? What if the two drugs do not show bioequivalence? Does it matter if afrezza is not as effective as Novolog? or can the drug still pass the FDA because it will improve medical adherence? Estimates from the World Health Organization (2003) indicate that only about 50% of patients with chronic diseases living in developed countries follow treatment recommendations.[1] In particular, low rates of adherence to therapies for asthma, diabetes, and hypertension are thought to contribute substantially to the human and economic burden of those conditions.ISn't this what really matters? Who wins this game, Al Mann and Mannkind shareholders, or Big Pharma?

Novolog Sales Data

Rank40

Currentsalesrank, all U.S.Pharmaceuticals.

Last updated:August 2013 (updated quarterly).
The followingdatashowsNovologU.S. retail sales in Q2 2013 compared to previous quarters.

Q2 2013	40 (2)	$319,752	-0.94%	2,975	-2.14%
Q1 2013	42 (3)	$322,779	3.74%	3,040	-10.03%
Q4 2012	39 (5)	$311,150	5.87%	3,379	8.54%
Q3 2012	44 (10)	$293,893	8.83%	3,113	3.53%
Q2 2012	54 (3)	$270,047	1.41%	3,007	0.91%
Q1 2012	57 (6)	$266,305	5.67%	2,980	3.72%
Q4 2011	63 (3)	$252,015	0.97%	2,873	-0.48%
Q3 2011	60 (1)	$249,591	-0.96%	2,887	-2.66%
Q2 2011	61 (5)	$252,010	3.16%	2,966	-0.70%
Q1 2011	66	$244,297		2,987